Investing.com - Edwards Lifesciences (NYSE: EW) reported fourth quarter EPS of $0.64, in line with the analyst estimate of $0.64. Revenue for the quarter came in at $1.53B versus the consensus estimate of $1.5B.
Guidance
Edwards Lifesciences sees Q1 2024 EPS of $0.62-$0.66 versus the analyst consensus of $0.67.
Edwards Lifesciences sees Q1 2024 revenue of $1.53B-$1.61B versus the analyst consensus of $1.56B.
Edwards Lifesciences sees FY 2024 EPS of $2.70-$2.80 versus the analyst consensus of $2.75.
Edwards Lifesciences sees FY 2024 revenue of $6.30B-$6.60B versus the analyst consensus of $6.48B.
Edwards Lifesciences's stock price closed at $88.23. It is up 37.41% in the last 3 months and up 10.23% in the last 12 months.
Edwards Lifesciences saw 4 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Edwards Lifesciences's stock price’s past reactions to earnings here.
According to InvestingPro, Edwards Lifesciences's Financial Health score is "great performance".
Check out Edwards Lifesciences's recent earnings performance, and Edwards Lifesciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar